Danaher is in line to exit proteomics platform developer IsoPlexis in a Nasdaq Global Market offering with a $100m placeholder target.
IsoPlexis, a US-based proteomics platform developer backed by life sciences and technology group Danaher, has filed on Tuesday to raise up to $100m in an initial public offering.
Founded in 2013, IsoPlexis has developed a single-cell proteomics platform used to study proteins and single-cell biology for the purpose of cancer immunology, cell and gene therapy development.
The company’s products include IsoSpark proteomics instruments ansd IsoCode and CodePlex chip consumables as well as dedicated software. Its revenue grew from $7.5m…
